Real-World Use of Adjuvant Nivolumab for Resected Stage III–IV Melanoma: 2-Year Analysis of AdjuMel - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Evaluation of Adjuvant Nivolumab in Patients with Resected Stage III–IV Melanoma: Two-Year Findings from the AdjuMel Study

  • By

  • Stéphane Dalle

  • Philippe Saiag

  • Céleste Lebbé

  • Jean-Jacques Grob

  • Brigitte Dréno

  • Sophie Dalac

  • Bernard Asselain

  • François Skowron

  • Sophie Darras

  • Nicolas Jovenin

  • Gaëlle Quereux

  • Amir Khammari

  • Capucine Rieuf

  • Florence Brellier

  • Laurent Mortier

  • August 29, 2026

Share

Clinical Scorecard: Evaluation of Adjuvant Nivolumab in Patients with Resected Stage III–IV Melanoma: Two-Year Findings from the AdjuMel Study

At a Glance

CategoryDetail
ConditionResected Stage III–IV Melanoma
Key MechanismsNivolumab is an anti-PD-1 agent that enhances immune response against melanoma cells.
Target PopulationAdults aged ≥ 18 years with completely resected stage III–IV melanoma.
Care SettingRoutine clinical practice in dermatology or oncology care facilities in France.

Key Highlights

  • At 2 years, relapse-free survival reached 52.8%.
  • Recurrence or death was less frequent in patients with stage IIIA disease compared to stage IIIB–D.
  • Tumor ulceration was linked to a higher risk of recurrence or death.
  • Nivolumab's safety profile was consistent with earlier reports.
  • Findings align with the randomized controlled CheckMate 238 study.

Guideline-Based Recommendations

Diagnosis

  • Patients should have a primary melanoma diagnosis with lymph-node involvement or resectable metastatic disease.

Management

  • Adjuvant nivolumab is recommended for patients with completely resected stage III–IV melanoma.

Monitoring & Follow-up

  • Patients should be followed for 5 years after the initial nivolumab infusion.

Risks

  • Tumor ulceration is associated with increased risk of recurrence or death.

Patient & Prescribing Data

Adults aged ≥ 18 years with resected stage III–IV melanoma.

Nivolumab is administered at 240 mg every 2 weeks or 480 mg every 4 weeks.

Clinical Best Practices

  • Systematic sampling for patient selection should be employed.
  • Participating physicians should enroll every consecutive patient meeting eligibility criteria.

Related Resources & Content

Original Source(s)

Real-World Use of Adjuvant Nivolumab for Resected Stage III–IV Melanoma: 2-Year Analysis of AdjuMel

  • by Stéphane Dalle, Philippe Saiag, Céleste Lebbé, Jean-Jacques Grob, Brigitte Dréno, Sophie Dalac, Bernard Asselain, François Skowron, Sophie Darras, Nicolas Jovenin, Gaëlle Quereux, Amir Khammari, Capucine Rieuf, Florence Brellier, Laurent Mortier

  • August 29, 2026

Related Content

Publisher Correction: Decade-long persistence of CD19 CAR T cells in B cell lymphomas

FDA Approves Daraxonrasib for Metastatic Pancreatic Cancer Following Landmark Clinical Trial Led by Dana-Farber

he U.S. Food and Drug Administration (FDA) has approved daraxonrasib, an oral multi-selective RAS(ON) inhibitor, for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy.

  • by

  • August 26, 2026

  • 5 min
Cognitive Behavior vs Bright Light Therapy for Insomnia in Women Undergoing Chemotherapy for Breast Cancer: A